The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.
White House withdraws Dr. Heidi Overton’s FDA commissioner nomination amid Senate GOP pushback, Pfizer and Verismo advance in vivo CAR-T manufacturing through new licensing deals, and Infinitus’s Ankit Jain discusses balancing workloads between humans and agentic AI.
Verismo Therapeutics licenses in vivo CAR T engineering technology from Stanford Medicine, while Pfizer licenses in vivo CAR-T programs from Starna Therapeutics.
Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica and Wilserdly for ESR1-mutated breast cancer, and Infinitus’s Ankit Jain talks agentic AI’s role in pharma’s commercial model.